An Interventional Decentralized Phase 2, Randomized, Double-Blind, 2-Arm Study to Investigate the Efficacy and Safety of Orally Administered Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir in Participants with Long COVID

This decentralized trial is a Phase 2, 1:1 randomized, double-blind, superiority, placebo-controlled study in an anticipated 100 non-hospitalized highly symptomatic adult participants with long COVID. It seeks to determine the efficacy, safety, and tolerability of 15 days of Paxlovid (nirmatrelvir/ritonavir), an anti-viral agent, compared with placebo plus ritonavir. The hypothesis is that viral persistence contributes to long COVID in some patients and nirmatrelvir/ritonavir compared with placebo/ritonavir can improve general health status in participants with long COVID. The study will also seek immune signatures associated with treatment response (overseen by Professor Akiko Iwasaki).
The decentralized study does not require site visits, and participants in all 48 states including the District of Columbia, who meet entry criteria can enroll. It is designed to make it convenient to participate. The study drugs will be delivered to the participant's designated address.
Long COVID is also known as post-acute sequelae of SARS-CoV-2 (PASC).

开始日期2023-04-14

申办/合作机构

Yale University

[+1]

NCT05545319

/ Withdrawn临床2期

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED NIRMATRELVIR/RITONAVIR COMPARED WITH PLACEBO/RITONAVIR FOR THE TREATMENT OF SEVERE COVID-19 IN HOSPITALIZED PARTICIPANTS WHO ARE IMMUNOCOMPROMISED OR AT INCREASED RISK FOR SEVERE COVID-19 OUTCOMES

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19

开始日期2022-12-13

申办/合作机构

Pfizer Inc.

NCT05441215

/ Completed临床1期

A PHASE I, MULTIPLE DOSE, OPEN-LABEL PHARMACOKINETIC STUDY OF NIRMATRELVIR/RITONAVIR IN HEALTHY LACTATING WOMEN

The main purpose of this study is to measure the level of active ingredient of the study medicine (nirmatrelvir) that is secreted in human breast milk when it is given to healthy breastfeeding women. The study medicine consists of two medicines, nirmatrelvir and ritonavir. We are seeking female participants who are:
* Actively breast-feeding (lactating) at least 12 weeks postpartum;
* Age between 18 to 55 years and not currently pregnant;
* Have a Body Mass Index (BMI): 17.5 kg/m2; and a total body weight >50 kg (110 lb).
Participants will take the study medicine by mouth for a total of 3 times over 2 days (2 morning doses and 1 evening dose) at the study clinic. We will periodically collect breast milk from day 2 to 4 to measure the level of nirmatrelvir and ritonavir in it. A safety follow up call will be conducted around 28-35 days from the last dose to monitor any reactions participants may have to the study medicine.

开始日期2022-12-12

申办/合作机构

Pfizer Inc.

100 项与奈玛特韦相关的临床结果

登录后查看更多信息

100 项与奈玛特韦相关的转化医学

登录后查看更多信息

100 项与奈玛特韦相关的专利（医药）

登录后查看更多信息

1,978

项与奈玛特韦相关的文献（医药）

2025-12-31·ANNALS OF MEDICINE

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study

Article

作者: Cuccurullo, F. ; Scotto, R. ; Buonomo, A. R. ; D’Agostino, A. ; Palmieri, S. ; Viceconte, G. ; Silvitelli, M. ; Grimaldi, F. ; Moccia, M. ; Mercinelli, S. ; Gentile, I. ; Gravetti, A. ; Pietroluongo, D. ; Trastulli, F.

BACKGROUND:

Immunocompromised patients are at high risk of developing persisting/prolonged COVID-19. Data on the early combined use of antivirals and monoclonal antibodies in this population are scarce.

RESEARCH DESIGN AND METHODS:

We performed an observational, prospective study, enrolling immunocompromised outpatients with mild-to-moderate COVID-19, treated with a combination of sotrovimab plus one antiviral (remdesivir or nirmatrelvir/ritonavir) within 7 days from symptom onset. Primary outcome was hospitalization within 30 days. Secondary outcomes were: needing for oxygen therapy; development of persistent infection; death within 60 days and reinfection or relapse within 90 days.

RESULTS:

We enrolled 52 patients. No patient was hospitalized within 30 days of disease onset, required oxygen administration, died within 60 days, or experienced a reinfection or clinical relapse within 90 days.The clearance rates were 67% and 97% on the 14th day after the end of therapy and at the end of the follow-up period, respectively.Factors associated with longer infection were initiation of therapy 3 days after symptom onset and enrollment for more than 180 days from the beginning of the study. However, only the latter factor was independently associated with a longer SARS-CoV-2 infection, suggesting a loss of efficacy of this strategy with the evolution of SARS-CoV-2 variants.

CONCLUSIONS:

Early administration of combination therapy with a direct antiviral and sotrovimab seems to be effective in preventing hospitalization, progression to severe COVID-19, and development of prolonged/persisting SARS-CoV-2 infection in immunocompromised patients.

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of outpatient COVID-19 antiviral treatment with nirmatrelvir/ritonavir versus usual care in Swedish patients with various risk factors

Article

作者: Gerdesköld Rappe, Christian ; Aldvén, Martina ; Mugwagwa, Tendai ; Nilsson, Fredrik

AIMS:

Nirmatrelvir/ritonavir (NMV/r) is an orally administered antiviral indicated for the outpatient treatment of adult patients with mild-to-moderate COVID-19 at high risk for disease progression to severe illness. We estimated the cost-effectiveness of NMV/r versus best supportive care for 54 patient cohorts, specified according to age, vaccination status and comorbidity burden.

MATERIALS AND METHODS:

A previously published and validated cost-effectiveness model was utilized and adapted to the Swedish setting. The model used a short-term decision-tree (1 year) followed by a lifetime 2-state Markov model. The short-term decision-tree captured costs and outcomes associated with the primary infection. Post-acute COVID-19 syndrome was only considered in terms of quality-of-life decrements for one year. Baseline hospitalization and mortality risks were taken from a Swedish, nationwide, uniquely granular, Omicron-era, real-world study. NMV/r effectiveness were taken from an Omicron-era US real-world study. Remaining inputs were informed by previous COVID-19 studies and publicly available Swedish sources.

RESULTS:

The incremental cost-effectiveness ratios (ICERs) showed a large variation ranging from almost nine million SEK for some of the youngest cohorts to being dominant (i.e. cost-saving with higher gains in quality-of-life vs standard of care) for twelve elderly cohorts. In general, higher age in combination with non-recent (>180 days) or no vaccination led to lower ICERs. Specifically, NMV/r was cost-effective for all but one patient cohorts at least 70 years old, and for most patient cohorts 60-69 years old.

LIMITATIONS:

As the COVID-19 landscape changes, symptom burden and baseline risks constantly change. Thus, the cost-effectiveness of NMV/r will change with time. However, the future risks could be related to the risks in the current study, and thus remain useful for decision makers.

CONCLUSIONS:

This study shows that NMV/r is a cost-effective or even cost-saving treatment option for many patient cohorts, including most elderly and not-recently vaccinated patients with at least some comorbidity burden.

2025-12-31·RENAL FAILURE

Safety and tolerability of molnupiravir and nirmatrelvir/ritonavir in patients with advanced chronic kidney disease and kidney failure; a cohort study

Article

作者: Moreno, Daiana ; Ouyang, Tianqi ; Sawtell, Rani ; Mejia, Sherley M. ; Sise, Meghan E. ; Strohbehn, Ian

Patients with advanced chronic kidney disease (CKD) and kidney failure were excluded from clinical trials that led to approval of molnupiravir and nirmatrelvir/ritonavir for COVID-19. Between November 2022 and February 2024 there were 100 patients with advanced CKD (N = 81) or kidney failure (N = 19) who received either molnupiravir (N = 40) or nirmatrelvir/ritonavir (N = 60) for COVID-19 within a large healthcare network. Ten (10%) patients were hospitalized within 30 days; 5 hospitalizations were COVID-19 related and 5 were unrelated to COVID-19. Adverse events documented in the electronic health record were uncommon and all were mild to moderate (grade 1 or 2). Despite use of numerous concomitant medications known to interact with nirmaltrelvir/ritonavir, we found no adverse events attributed to a drug-drug interaction. All patients survived >30 days and 3 (3%) died prior to 90 days. Molnupiravir and nirmatrelvir/ritonavir were safe and well tolerated in patients with advanced CKD and kidney failure.

594

项与奈玛特韦相关的新闻（医药）

2025-06-06

·微信

新冠感染肺肠共治新策略：一品红独家医保中药复方香薷水临床价值凸显

01临床需求凸显：新冠合并胃肠症状治疗缺口待填补中国疾病控制中心发布数据显示，近期新冠病毒感染上升趋势明显，新型冠状病毒感染已成为急性呼吸道病毒感染的第一位。然而，部分患者感染后除了出现常见的发热、咳嗽、头痛肌痛、乏力等症状外，还会出现恶心、呕吐、腹泻、腹痛等胃肠道症状。新冠病毒可通过胃肠道高表达的ACE2受体进入胃肠道细胞，直接损害胃肠道器官，引发一系列胃肠道不适。一项meta分析纳入了60项研究共4243例患者(大多数来自中国)，发现胃肠道症状的总患病率达17.6%，最常见的胃肠症状为厌食(26.8%)，其次为腹泻(12.5%)、恶心/呕吐(10.2%)和腹痛(9.2%)[1]。新冠病毒感染合并胃肠症状的治疗并不能忽视，已有研究表明，新冠病毒感染合并胃肠症状患者更易发展为重症[2]，需加强警惕。新冠病毒感染合并胃肠道症状存在“肺肠共病”问题，目前临床上“肺肠同治”治疗用药仍然缺乏，形成临床需求。针对新冠病毒感染的抗病毒药物治疗近年来取得显著进展，国内已有多款抗病毒药物获批，包括奈玛特韦/利托那韦、莫诺拉韦、先诺特韦/利托那韦、氢溴酸氘瑞米德韦、来瑞特韦等，抗新冠病毒药物通过抑制病毒复制降低重症风险，尤其适用于高危人群。但新冠合并胃肠道症状患者针对性治疗方案明显不足，目前采用对症治疗为主，对症治疗可能涉及多种化药联合，存在达不到用药指征或多药联合导致患者依从性差、安全性等问题，形成显著的临床需求缺口。中成药具备单一用药即可缓解多种胃肠道症状的优势，但目前针对新冠病毒感染合并胃肠道症状的治疗中，具有“肺肠同治”、“一药双效”——既可治疗病毒感染引起发热、头痛、肌痛等全身症状，又能同时缓解厌食、腹泻等多种胃肠症状的中药产品仍存在缺口。这个缺口不仅存在于新冠病毒感染的治疗中，在流行性感冒、普通感冒合并胃肠道症状的治疗中同样存在。02经典组方创新应用：复方香薷水肺肠同治填补治疗缺口复方香薷水源自宋代《太平惠民和剂局方》香薷饮，经现代工艺改良而成，具有解表化湿，醒脾和胃功效，从中医理论而言形成"解表-化湿-和中"的立体治疗作用，起到“肺肠同治”的治疗效果，这种"一药双效"的特点，既避免了多种药物联用负担，又符合中医"肺与大肠相表里"的整体观。复方香薷水用皱叶香薷作为君药，皱叶香薷发汗解表见长，作用偏在表对感冒作用强，同时具有化湿和中作用，因此有“夏月麻黄”之称，对感冒症状和胃肠道症状均有较好的治疗作用。相对于同类产品藿香正气制剂以“广藿香”为君药，广藿香功效偏化湿和中，对胃肠道症状能较好的缓解，但对感冒症状作用偏弱。国家健康卫生委基层卫生健康司发布的《农村居民新冠病毒感染防治健康教育手册》、中华中医药学会发布《新型冠状病毒感染胃肠功能紊乱中医诊疗专家共识》及《河北省新冠病毒感染者和密接人员居家中药干预指引》等指南共识中均推荐复方香薷水治疗新冠病毒感染合并胃肠症状。复方香薷水也是首个以肺-肠轴解码药效与作用机制的中药产品，对填补上呼吸道病毒感染合并胃肠道症状“肺肠同治”治疗用药空缺，未来市场可期。目前，广州呼吸健康研究院杨子峰教授团队正在开展基于“肺肠同治”探讨复方香薷水调节肺肠微生态及免疫反应发挥流感感染防治作用的研究，研究结果值得期待。03独家医保优势：蓝海市场待开拓复方香薷水作为国家医保乙类独家品种，三大市场机会突显：1.复方香薷水满足新冠、流感等呼吸道病毒感染合并胃肠道症状患者用药需求，且同类产品少，具有产品竞争优势及广州呼吸健康研究院等循证研究支持；2.国家医保覆盖降低患者用药门槛，医疗机构采购意愿强；3.独家品种价格渠道稳定，复方香薷水竞争品类同类产品本身较少，缺乏独家产品，复方香薷水为一品红独家，价格渠道更可控。面对新冠、流感等呼吸道病毒感染存在合并胃肠道症状"肺肠同病"的临床挑战和市场用药空缺，复方香薷水凭借经典组方、独特疗效和独家医保优势，正开启中医药“肺肠同治”治疗的新篇章。一品红将持续深化循证医学研究，加强渠道布局，让这一千年古方焕发现代医疗价值。商务咨询热线:4001833668参考资料：[1]Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal Manifestations of SARS - CoV - 2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta - analysis[J]. Gastroenterology, 2020, 159(1):81. Epub 2020 Apr 3.[2]Yunle Wan,Ping Lan,,et. Enteric involvement in hospitalised patients with COVID-19 outside Wuhan. Lancet Gastroenterology & Hepatology.2021.END*声明：此篇文章受众仅为医药、医疗等健康产业专业伙伴，仅供医学药学专业人士使用，不针对普通消费大众。

2025-05-28

·梅斯医学

钟南山：目前新冠疫情仍处于高峰期

5月24日，在2025年广州科技活动周开幕式上，中国工程院院士、广州国家实验室主任钟南山通透露了近期流感、新冠疫情等公共卫生领域的最新进展。“近来，新冠流行仍处于高峰期。”钟南山表示，从3月初到5月初，中国香港特别行政区和新加坡、英国、法国、巴西、挪威的监测数据均显示，感染新冠病毒的人数呈现增加趋势。钟南山预测，目前仍处在爬坡阶段，预计6月底前结束流行，持续6至8周时间。据钟南山介绍，此轮中国的新冠病毒毒株主要是XDV和XDV. 1，新毒株的特点突出，一方面，免疫逃逸更强，之前已感染过或者打过疫苗的，也可能再次感染；另一方面，毒株毒力较弱，患者症状更轻，例如嗓子痛、低烧、咳嗽或根本没有症状，容易被忽视。广州医科大学附属市八医院感染病中心首席专家蔡卫平在接受采访时也表示：“当前发热门诊病例总数未明显增加，尽管新冠阳性占比翻倍，但住院重症患者极少，目前医院感染ICU里暂无危重症病例。”另外，对于此次新冠流行的原因，南方医科大学南方医院感染内科副主任彭劼认为，上一次新冠的小高峰发生在2024年7—10月，距今已过去半年，随着人们抗体水平的降低或消失，新一波感染就有可能发生，因此，此波发病属疾病的自然现象。此外，春夏换季，早晚温差大，是本就容易中招的感冒高发期。彭劼还强调，确诊新冠后尽早使用抗病毒药物（如奈玛特韦/利托那韦等），可显著缩短病程。“抗病毒药物在感染早期使用效果最佳，能有效抑制病毒复制，缩短病程，降低重症风险。从临床观察来看，它的副作用较小，安全性良好。若未能及时就医，可临时服用退烧、止痛药物减轻不适。”中国疾病预防控制中心提醒，当前呼吸道传染病疫情总体处于较低水平，托幼机构、学校等人群聚集场所存在发生聚集性疫情的风险，应做好呼吸道传染病的防范。建议公众采取以下防护措施：保持良好卫生习惯：咳嗽或打喷嚏时，用纸巾、毛巾或手肘遮住口鼻；注意手卫生，避免用不洁净的手触摸眼、鼻、口，以减少病原体传播风险。倡导健康生活方式：要均衡饮食、适量运动和充足休息，增强身体免疫力。出现发热、咳嗽或其他呼吸道感染症状时，与人接触要佩戴口罩，保持室内良好通风；根据需要及时就医。科学佩戴口罩：在就医过程中需全程佩戴口罩；在人群密集场所或乘坐公共交通工具（如飞机、火车、地铁等）时建议佩戴口罩，尤其是老年人和一些有慢性基础性疾病的患者，可以减少感染风险。积极主动接种疫苗：免疫力较弱人群（如孕妇、低龄儿童、老人及慢性病患者等）应根据疫苗接种指引接种预防呼吸道传染病的相关疫苗。撰文 | 梅斯医学编辑 | 阿拉斯加宝● 每一口都可能折寿？最新研究：多吃这类食品，癌症、全因死亡、肝病风险升高，且加速衰老！但这些食物可以缓解●这几种维生素能加速新冠患者康复？Nature子刊：不仅让超一半患者2周内恢复体力，还能调节肠道，缓解后遗症，促进抗体生成●热议！取鱼刺花了85元，患者嫌贵，要投诉！网友：我曾在美国拔鱼刺花了1万元，为何这么不知足？鱼刺位置决定收费，医生的价值要被尊重版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

疫苗AHA会议

2025-05-26

·健识局

明星也中招新冠病毒！普通人如何应对？

在2025年的初夏，新冠病毒再度成为热议话题。5月15日，知名歌手陈奕迅确诊新冠肺炎，立即停止了所有演出活动并进行休养。社交媒体上，也有不少人表示又“阳”了，发热、咳嗽、喉咙痛……中国疾控中心监测数据表明，新冠病毒处于一轮活跃期，门急诊流感样病例中的新冠阳性率已连续三周上升，在门急诊流感样病例中位居首位，到5月4日已升至16.2%，相当于每6个门急诊呼吸道感染患者中就有1个新冠患者。专家表示，新毒株致病力未显著增强，其带来的症状与之前相比没有明显变化，需要住院的重症也不多。不过，对于小孩、老人、孕妇和有基础病的高危人群而言，新冠仍然可能会导致严重的后果。因此，治疗新冠的药物仍然是刚需。每次新冠病毒来袭，治疗药物就会受到追捧。国内已有七款抗新冠病毒的化学药物上市，也有中成药活跃在临床一线。康缘药业是国内新冠治疗中药品类最全的企业之一，打造了“新冠治疗矩阵”：散寒化湿颗粒纳入第十版等多版新冠诊疗方案，被推荐对于重型、危重型患者；金振口服液、热毒宁注射液则补齐了儿童没有专用药的缺口。专家普遍认为，有了丰富的药物储备，这一轮的新冠流行无须过度担忧。新冠病毒再“抬头”造成这一轮新冠流行的罪魁祸首，是奥密克戎家族的 XDV 变异株及其新分支。其中，新分支NB.1.8.1占据了主要流行地位。体外试验数据表明，NB.1.8.1的感染力和抗体逃逸能力都有明显提高，但致病力未见显著变化，重症率未超过2024年峰值。其实这一轮新冠活跃期在3月就有苗头，不少患者表现多为中低程度的发热、咽痛、咳嗽，症状要比流感更轻。很多临床医生认为，这一轮新冠流行并不值得特别担忧。不过，美团买药健康指数显示，近期广州、深圳新冠用药搜索量较上周增长85%、75%，主要搜的就是新冠检测试剂、抗病毒药、新冠特效药等；多款新冠药物销量随之上升。目前，本轮新冠疫情还没有到达传播的最高峰，南方地区新冠病毒检出率还在上升。有专家根据趋势判断，真正的高峰应于5月下旬达到。对公众而言，新冠卷土重来的剧本已经不陌生，这两年来新冠传播多次抬头，未来全球范围内新冠病毒传播会反复出现。好在，如今应对新冠病毒我们已经有了丰富的药物储备。目前，国内已有七款抗新冠病毒的化学药物上市，既包括进口的莫诺拉韦、奈玛特韦/利托那韦片，又包括先诺特韦/利托那韦、阿兹夫定等五款国产药。被市场广泛关注的还有中药，比如康缘药业的散寒化湿颗粒、以岭的连花清瘟胶囊、步长的宣肺败毒颗粒等。“新冠治疗矩阵”如何抗新冠寒湿疫方，又被称为“武汉抗疫一号方”，是中国科学院院士仝小林在当年的武汉前线根据寒湿疫理论拟定的中医通治方，也是第一个由武汉官方发文推行的协定处方。康缘药业的散寒化湿颗粒正是来自寒湿疫方。此前，散寒化湿颗粒曾与辉瑞的“新冠神药”P药进行头对头临床研究，这是全球首个中药对西药的多中心轻/中型新型冠状病毒感染头对头研究。结果显示：服用散寒化湿颗粒的轻、中型新冠患者在咳嗽、咽痛、乏力的消失时间、体温恢复时间等方面均优于P药组。儿童感染新冠是家长最头疼的事情，小孩吃大人药总会碰到剂量和副作用等各种麻烦，但国内的“新冠特效药”都是面向成年人的，这怎么办？康缘药业的金振口服液儿童新冠病毒感染防治的首选品牌，也是目前第一个完成儿童新冠病毒感染临床研究的儿童专用药。经过针对儿童随机双盲多中心临床医学实验，被证明对新冠患者阳性转阴时间缩短，临床症状减轻，退热止咳抗炎等均有显著效果。此外，康缘药业的热毒宁注射液，也是国内唯一开展儿童十万例真实世界研究的清热解毒类中药注射剂，对腺病毒、流感病毒、呼吸道合胞病毒、鼻病毒、新冠病毒等多种呼吸道病毒均有明显抑制作用。热毒宁注射液曾针对新冠开展四项临床研究结果，证明其可显著缩短核酸检测转阴时间、住院时间、退热时间、临床症状痊愈时间，提高影像学好转率，显著降低患者炎症水平，安全性好。2023年1月，国家卫健委公布的第十版新冠诊疗方案中，热毒宁注射液被推荐对于重型、危重型患者，成人、儿童都可放心使用。每一轮的新冠抬头，都是对公共卫生体系的一次压力测试。着眼未来，只要新冠病毒不消失，公众就有用药需求。从西药到中药，中国的新冠药物矩阵已经为老人、幼儿、慢病患者群体织就了一张健康保障网。撰稿丨方涛之编辑丨江芸贾亭运营｜李木子插图｜视觉中国声明：健识局原创内容，未经许可请勿转载上海大三甲医生薪酬改革；971全国断供；美敦力拆分中国3.5亿烟民，却没有诞生一个爆款戒烟药？“国家喊你减肥” 带动这个千亿产业增长天猫健康今年投入5亿建赛道

疫苗临床研究

100 项与奈玛特韦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	奈玛特韦	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床3期	巴西	Pfizer Inc.	2021-07-16
新型冠状病毒感染	临床3期	俄罗斯	Pfizer Inc.	2021-07-16
新型冠状病毒感染	临床3期	韩国	Pfizer Inc.	2021-07-16
新型冠状病毒感染	临床3期	西班牙	Pfizer Inc.	2021-07-16
新冠肺炎后遗症	临床2期	美国	Pfizer Inc.	2023-04-14
严重急性呼吸综合征	临床2期	美国	Pfizer Inc.	2022-12-13
严重急性呼吸综合征	临床2期	保加利亚	Pfizer Inc.	2022-12-13
肝损伤	临床1期	美国	Pfizer Inc.	2021-08-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05567952 (CTgov)	临床2期	新型冠状病毒感染	436	Nirmatrelvir+Ritonavir (Nirmatrelvir 300 mg + Ritonavir 100 mg)	遞觸範糧廠獵齋憲淵鏇(簾鬱遞鏇淵憲餘窪積簾) = 願淵觸窪夢範鹽憲鬱鬱構鹹齋鹹獵鬱憲顧顧製 (範膚簾鏇顧鑰鹽衊餘糧, 0.129) 更多	-	2024-10-08
				Placebo+Ritonavir (Placebo + Ritonavir 100 mg)	遞觸範糧廠獵齋憲淵鏇(簾鬱遞鏇淵憲餘窪積簾) = 觸膚構鏇艱鬱製鹹顧壓構鹹齋鹹獵鬱憲顧顧製 (範膚簾鏇顧鑰鹽衊餘糧, 0.171) 更多
NCT05576662 (STOP-PASC, CTgov)	临床2期	新冠肺炎后遗症	168	Nirmatrelvir+ritonavir (Nirmatrelvir Plus Ritonavir)	範夢憲觸鹹簾觸蓋夢繭 = 顧襯醖構鹽夢構鏇膚艱膚願糧膚遞淵製壓鬱選 (遞繭廠蓋築壓獵鬱鑰鏇, 膚醖襯觸簾膚鏇鏇鏇襯 ~ 鹽製獵齋膚構繭願鬱製) 更多	-	2024-09-25
				Placebo+ritonavir (Placebo Plus Ritonavir)	範夢憲觸鹹簾觸蓋夢繭 = 鹽築顧鬱願淵窪網願膚膚願糧膚遞淵製壓鬱選 (遞繭廠蓋築壓獵鬱鑰鏇, 糧齋糧積鏇鏇膚願製鹽 ~ 製網膚範壓顧獵範蓋壓) 更多
NCT05438602 (CTgov)	临床2期	新型冠状病毒感染	158	Placebo+Nirmatrelvir+Ritonavir (Nirmatrelvir + Ritonavir 5 Day Then Placebo 10 Day)	艱製範艱鹹繭製積淵窪 = 範憲製壓遞選襯鬱襯遞簾觸鹽夢糧窪構鏇觸鑰 (繭顧鹹鏇膚齋選廠選築, 構觸選衊選窪繭醖膚願 ~ 顧選衊蓋範鑰遞醖蓋顧) 更多	-	2024-09-23
				Placebo+Nirmatrelvir+Ritonavir (Nirmatrelvir + Ritonavir 10 Day Then Placebo 5 Day)	艱製範艱鹹繭製積淵窪 = 蓋襯願鹽簾壓夢憲積觸簾觸鹽夢糧窪構鏇觸鑰 (繭顧鹹鏇膚齋選廠選築, 範蓋鏇觸衊鏇淵膚憲壓 ~ 廠膚顧醖製鏇廠繭糧鬱) 更多
NCT05487040 (CTgov)	临床1期	新型冠状病毒感染	15	PF-07321332 (nirmatrelvir)+ritonavir (Cohort 1 (No HD))	餘壓鹹壓憲觸構願積蓋 = 醖選鑰淵憲窪廠範夢艱壓衊窪衊膚衊簾夢構醖 (淵鹽衊鹽簾壓構夢鹽糧, 衊網鏇窪壓簾鑰選淵廠 ~ 鹽築製鬱簾範窪齋襯積) 更多	-	2024-09-23
				PF-07321332 (nirmatrelvir)+ritonavir (Cohort 2 (Intermittent HD))	餘壓鹹壓憲觸構願積蓋 = 簾鹽蓋窪築壓蓋餘鹽構壓衊窪衊膚衊簾夢構醖 (淵鹽衊鹽簾壓構夢鹽糧, 衊選鏇積窪範鹹築顧淵 ~ 積醖鬱醖襯簾窪衊鹹襯) 更多
NCT05011513 (EPIC-SR, Pubmed) 人工标引	临床2/3期	新型冠状病毒感染	1,288	Nirmatrelvir-riritonavir	淵製壓憲餘鏇醖憲築廠(獵膚醖壓淵窪繭積壓廠) = 積簾鑰選繭顧觸膚醖鏇廠夢壓糧顧艱糧糧廠蓋 (製願築願網鬱蓋繭蓋鏇 ) 更多	不佳	2024-04-04
				Placebo	淵製壓憲餘鏇醖憲築廠(獵膚醖壓淵窪繭積壓廠) = 願壓窪襯餘簾簾廠壓鏇廠夢壓糧顧艱糧糧廠蓋 (製願築願網鬱蓋繭蓋鏇 ) 更多
NCT05005312 (CTgov)	临床1期	肝损伤	17	PF-07321332+ritonavir (Normal Hepatic Function)	網壓願糧齋廠繭鏇憲壓(構獵範獵鑰鹹衊齋觸願) = 獵築顧繭餘壓膚構築窪網壓範衊網構範蓋窪夢 (膚餘糧積夢衊鹽選廠鹹, 20) 更多	-	2023-09-06
				PF-07321332+ritonavir (Moderate Hepatic Impairment)	網壓願糧齋廠繭鏇憲壓(構獵範獵鑰鹹衊齋觸願) = 襯範簾製衊齋壓齋鑰獵網壓範衊網構範蓋窪夢 (膚餘糧積夢衊鹽選廠鹹, 48) 更多
NCT05011513 (EPIC-SR, CTgov)	临床2/3期	新型冠状病毒感染	1,440	Placebo	醖選遞淵夢艱窪鹹範衊(齋艱構鏇齋膚獵築築衊) = 齋顧遞鹽鑰憲遞膚顧壓壓齋觸餘壓襯簾簾鹹顧 (範廠廠鬱窪窪廠艱膚構, 鹹蓋製鹽遞簾遞鏇蓋膚 ~ 憲遞襯製壓壓糧鹽遞襯) 更多	-	2023-08-14
EPICOVIDEHA (EHA2023)	N/A	新型冠状病毒感染	1,859	Nirmatrelvir/ritonavir	襯艱醖範範廠襯獵窪顧(醖齋夢願餘構憲襯壓醖): aOR = 3.624 (95% CI, 1.619 ~ 8.109) 更多	-	2023-06-08
				No nirmatrelvir/ritonavir
NCT05047601 (CTgov)	临床2/3期	新型冠状病毒感染	2,954	Placebo for PF-07321332	鬱襯憲艱獵繭窪網簾餘 = 齋夢窪築鑰簾淵構鏇淵鬱築襯鑰廠鏇餘憲鬱窪 (選遞糧遞壓糧衊衊鬱遞, 夢簾觸憲膚壓製膚壓選 ~ 製簾壓鹽壓構製齋糧遞) 更多	-	2023-05-06
NCT04960202 (phase 3 randomized trial \| EPIC-HR, CTgov)	临床2/3期	新型冠状病毒感染	2,091	Placebo	壓憲範顧淵糧鑰網簾憲 = 襯醖選鬱鏇繭蓋淵夢憲鬱夢願鬱範夢衊窪獵顧 (夢餘齋淵鑰鑰築鹹壓艱, 願積製築構淵齋網鹹獵 ~ 鏇築蓋觸網構鏇淵齋構) 更多	-	2023-02-09